Is ventilator-associated pneumonia (VAP) linked to high mortality in severe COVID-19?

Ventilator-associated pneumonia (VAP) is a serious and potentially deadly complication that occurs in patients who are placed on mechanical ventilators. VAP is defined as pneumonia that develops 48 hours or more after endotracheal intubation, and is associated with a higher mortality rate compared to pneumonia acquired in the community.

The development of VAP in patients with severe COVID-19 who require mechanical ventilation has been a significant concern for healthcare providers, as it can lead to worse outcomes and increased mortality. In this research article, we will explore the link between VAP and high mortality in severe COVID-19 patients.

Background:

COVID-19, caused by SARS-CoV-2, has been declared a pandemic by the World Health Organization (WHO) since March 2020. COVID-19 primarily affects the respiratory system, and the most severe cases require mechanical ventilation to support breathing. Patients with severe COVID-19 who require mechanical ventilation are at increased risk of developing VAP due to various factors, including immune suppression, inflammation, and prolonged intubation. VAP can lead to prolonged hospital stays, increased morbidity, and mortality rates.

Epidemiology:

The incidence of VAP in COVID-19 patients requiring mechanical ventilation varies between studies, with reported rates ranging from 7.5% to 47%. In a study conducted in China, the incidence of VAP in COVID-19 patients requiring mechanical ventilation was 19.6%, and the mortality rate was 62.5% in patients who developed VAP. In a study conducted in Italy, the incidence of VAP in COVID-19 patients requiring mechanical ventilation was 47%, and the mortality rate was 93% in patients who developed VAP.

Pathogenesis:

The pathogenesis of VAP in COVID-19 patients is multifactorial and involves a complex interplay between the host immune response and the microorganisms colonizing the respiratory tract. COVID-19 leads to significant immune dysregulation, which can increase the risk of bacterial colonization and subsequent infection.

The virus may also directly damage the respiratory epithelium, leading to impaired mucociliary clearance and increased bacterial adherence. Finally, the prolonged use of mechanical ventilation can lead to changes in the respiratory tract microbiota, favoring the growth of potentially pathogenic bacteria.

Diagnosis:

The diagnosis of VAP in COVID-19 patients can be challenging, as the clinical and radiographic features of pneumonia may overlap with those of COVID-19 itself. The gold standard for diagnosis remains the microbiological confirmation of the pathogen, either by culture or molecular techniques.

However, obtaining a sputum or bronchoalveolar lavage sample can be difficult in intubated COVID-19 patients, and false-negative results are common. Clinical scores, such as the Clinical Pulmonary Infection Score (CPIS), can aid in the diagnosis of VAP in COVID-19 patients, but their diagnostic accuracy is limited.

Management:

The management of VAP in COVID-19 patients is similar to that in non-COVID-19 patients and includes early initiation of appropriate antibiotics and optimization of mechanical ventilation. However, the choice of antibiotics may be complicated by the emergence of antimicrobial resistance, especially in healthcare settings with high rates of multidrug-resistant organisms.

Moreover, the use of corticosteroids in COVID-19 patients can complicate the diagnosis of VAP, as it can mask the signs and symptoms of infection.

Prevention:

Preventing VAP in COVID-19 patients requires a multifaceted approach that includes early extubation whenever possible, implementation of infection prevention and control measures, and optimization of mechanical ventilation strategies. The use of non-invasive ventilation or high-flow nasal oxygen may be considered in selected patients to reduce the duration of intubation and the risk of VAP. Other measures that can help prevent VAP in COVID-19 patients include regular oral care, elevation of the head of the bed, and early mobilization.

Impact on Mortality:

VAP is associated with increased mortality in COVID-19 patients requiring mechanical ventilation. A study conducted in Italy found that the mortality rate in COVID-19 patients who developed VAP was 93%, compared to 18% in those who did not develop VAP. Similarly, a study conducted in China reported a mortality rate of 62.5% in COVID-19 patients who developed VAP, compared to 12.3% in those who did not develop VAP. VAP is also associated with longer hospital stays and increased healthcare costs.

Future Directions:

Given the high mortality rate associated with VAP in COVID-19 patients, there is a need for further research to better understand the pathogenesis of VAP in this population and to develop more effective prevention and management strategies. One promising approach is the use of prophylactic antibiotics in COVID-19 patients requiring mechanical ventilation to prevent the development of VAP. However, the potential risks and benefits of this approach need to be carefully evaluated in future studies.

A new Machine learning study links unresolving secondary pneumonia to mortality in patients with severe pneumonia, including COVID-19

We performed a single-center prospective cohort study of 585 mechanically ventilated patients with severe pneumonia and respiratory failure, 190 of whom had COVID-19, who underwent at least one bronchoalveolar lavage. A panel of ICU physicians adjudicated pneumonia episodes and endpoints based on clinical and microbiologic data. Given the relatively long ICU length of stay among patients with COVID-19, we developed a machine learning approach called CarpeDiem, which groups similar ICU patient-days into clinical states based on electronic health record data.

Results: CarpeDiem revealed that the long ICU length of stay among patients with COVID-19 is attributable to long stays in clinical states characterized primarily by respiratory failure. While VAP was not associated with mortality overall, mortality was higher in patients with one episode of unsuccessfully treated VAP compared with successfully treated VAP (76.4% versus 17.6%, p < 0.001). In all patients, including those with COVID-19, CarpeDiem demonstrated that unresolving VAP was associated with transitions to clinical states associated with higher mortality.

Conclusions: Unsuccessful treatment of VAP is associated with greater mortality. The relatively long length of stay among patients with COVID-19 is primarily due to prolonged respiratory failure, placing them at higher risk of VAP.

Conclusion:

VAP is a significant complication that can occur in COVID-19 patients requiring mechanical ventilation and is associated with increased mortality rates. Preventing and managing VAP in this population requires a multifaceted approach that includes infection prevention and control measures, early extubation whenever possible, and optimization of mechanical ventilation strategies. Further research is needed to better understand the pathogenesis of VAP in COVID-19 patients and to develop more effective prevention and management strategies.

reference link :

“Machine learning links unresolving secondary pneumonia to mortality in patients with severe pneumonia, including COVID-19” by Benjamin Singer et al. Journal of Clinical Investigation

Torres, A., Niederman, M. S., Chastre, J., Ewig, S., Fernandez-Vandellos, P., Hanberger, H., … & Welte, T. (2017). International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). European Respiratory Journal, 50(3), 1700582.

Martin-Loeches, I., Torres, A., Rinaudo, M., Terraneo, S., de Rosa, F., Ramirez, P., … & Bassetti, M. (2020). Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug-resistant organisms. Journal of Infection, 81(4), 614-620.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., … & Guan, L. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 395(10229), 1054-1062.

Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., … & Pesenti, A. (2020). Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. Jama, 323(16), 1574-1581.

Wang, Y., Lu, X., Li, Y., Chen, H., Chen, T., Su, N., … & Zhao, S. (2020). Clinical course and outcomes of 344 intensive care patients with COVID-19. American Journal of Respiratory and Critical Care Medicine, 201(11), 1430-1434.